Quick Answer
Silence Therapeutics plc reported Research And Development Expense of $67.75 million for the year ending 2025.
- Silence Therapeutics plc showed a decrease of -0.2% in Research And Development Expense from 2024 to 2025.
- This data is from Silence Therapeutics plc's annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $11.85 million | Q2 2024: $13.80 million | Q3 2024: $20.16 million | Q1 2025: $20.81 million | Q2 2025: $17.65 million | Q3 2025: $20.54 million.
- Over the full 7 years of available data (2019 to 2025), Silence Therapeutics plc's Research And Development Expense has grown by 408.0%.
- Historical annual values: Fiscal year 2025: $67.75 million | Fiscal year 2024: $67.88 million | Fiscal year 2023: $56.94 million | Fiscal year 2022: $43.55 million | Fiscal year 2021: $30.77 million | Fiscal year 2020: $20.21 million | Fiscal year 2019: $13.34 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: